$AUPH “Despite providing Benlysta treatment for twice as long as voclosporin, and setting the bar for renal response substantially lower, Benlysta still only managed to barely hit statistical significance. In light of these results, we regard the benefit of Benlysta in LN to be marginal, at best, similar to its benefit in systemic lupus erythematosus (SLE),” HC Wainwright analyst Ed Arce wrote in a December note.
  • 17